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Background: Hirano bodies are actin-rich paracrystalline inclusions found in brains of patients with Alzheimer’s
disease (AD), frontotemporal dementia (FTD), and in normal aged individuals. Although studies of post-mortem
brain tissue provide clues of etiology, the physiological function of Hirano bodies remains unknown. A cell culture
model was utilized to study the interactions of mutant tau proteins, model Hirano bodies, and GSK3β in human
astrocytoma cells.
Results: Most tau variants showed co-localization with model Hirano bodies. Cosedimentation assays revealed this
interaction may be direct, as recombinant purified forms of tau are all capable of binding F-actin. Model Hirano
bodies had no effect or enhanced cell death induced by tau in the absence of amyloid precursor protein
intracellular domain (AICD). In the presence of AICD and tau, synergistic cell death was observed in most cases, and
model Hirano bodies decreased this synergistic cell death, except for forms of tau that caused significant cell death
in the presence of Hirano bodies only. A role for the kinase GSK3β is suggested by the finding that a dominant
negative form of GSK3β reduces this synergistic cell death. A subset of Hirano bodies in brain tissue of both
Alzheimer’s disease and normal aged individuals was found to contain tau, with some Hirano bodies in Alzheimer’s
disease brains containing hyperphosphorylated tau.
Conclusion: The results demonstrate a complex interaction between tau and AICD involving activation of GSK3β in
promoting cell death, and the ability of Hirano bodies to modulate this process.
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Frontotemporal dementiaBackground
The cause of sporadic Alzheimer’s disease (AD) is un-
known, and an intricate interaction between multiple gen-
etic, epigenetic, and environmental risk factors has been
proposed (for review, see [1]). However, in approximately
1% of total AD cases, studies show that neurodegeneration
results from mutations in the genes encoding the amyloid
precursor protein (APP), presenilin 1 (PSEN1), or PSEN2
[2,3]. These mutations result in altered processing of APP,
increased deposition of amyloid-beta (Aβ), and early onset* Correspondence: furukawa@uga.edu
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unless otherwise stated.neurodegeneration. This led to the formation of the amyl-
oid cascade hypothesis, which posits that Aβ initiates a
cascade of events leading to tau deposition, synaptic dys-
function and cognitive decline [4]. Intramembrane prote-
olysis of APP by γ-secretase also releases an intracellular
fragment known as the amyloid precursor protein intra-
cellular domain (AICD). AICD has been shown to form
multi-protein complexes that regulate the induction of
apoptosis (for review, see [5,6]). Multiple studies sug-
gest that a downstream effector of AICD is the kinase
GSK3β. Studies in neuronal cell cultures and a mouse
model report that AICD induces upregulation of total
levels of GSK3β as well as increased activation, and thus
induces tau hyperphosphorylation [7-9]. Abnormal tauLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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phosphorylated tau levels correlate with the severity of
AD [12]. However, the precise mechanisms causing
abnormal tau phosphorylation leading to pathological
tau formation remain unclear.
Complementary to the amyloid cascade hypothesis was
the discovery that mutations in tau cause a familial neuro-
degenerative disease called frontotemporal dementia with
parkinsonism linked to chromosome 17 (FTDP-17) [13].
This disease and its sporadic (non-familial) counterparts,
known as frontotemporal lobar degeneration with tau-
positive inclusions (FTLD-tau), are characterized patho-
logically by the formation of neurofibrillary tangles (NFTs)
and other neuronal and glial inclusions composed of
hyperphosphorylated tau [14]. Aβ-containing plaques
found in AD are not considered a significant invariant
pathological feature of these tauopathies. Thus, the
amyloid cascade hypothesis posits that Aβ acts up-
stream of tau to promote neurodegeneration. Never-
theless, significant plaque pathology is often reported
in tauopathy patients’ brain tissue [15-19].
Hirano bodies are inclusion bodies found in significant
numbers in the hippocampus in patients with AD com-
pared to age matched controls [20]. In addition, Hirano
bodies are found in postmortem brain tissue of patients
afflicted with a variety of neurodegenerative and other
diseases including the tauopathies, and in normal aged
individuals [21,22], yet no studies to date explore the
cellular basis of this finding. Although the contribution
of Hirano bodies to tauopathy is unknown, cell culture
and transgenic animal models of FTDP-17 suggest that
alterations in the actin cytoskeleton and formation of
Hirano bodies are an important event in the pathogen-
esis of tauopathies [23-25]. Tau has been previously
shown to bind actin [26-28] and the interaction of tau
with the actin cytoskeleton could play a role in disease
progression. Hirano bodies are thought to be composed
primarily of filamentous actin and actin-associated pro-
teins [29-31], but they have also been shown to contain
other components of the neuronal cytoskeleton such the
microtubule associated protein tau [32,33]. Hirano bodies
also accumulate a number of signaling proteins including
the transcription factor FAC1 [34], transforming growth
factor-β3 [35], and AICD [36,37]. Interestingly, Hirano
et al., observed a positive correlation between the fre-
quency of NFTs and Hirano bodies in patient samples
[38]. In that study, Hirano bodies and NFTs were often
found in the same cell, although the specific isoforms,
mutants, or modifications on tau and physiological con-
sequences of this are unknown.
Early studies of Hirano bodies were reliant on immu-
nohistochemical staining of post-mortem brain tissue
due to lack of a model system to study their formation
or physiological function. We have developed a cellculture model of Hirano bodies by expressing a truncated
form of 34-kDa protein (CT) from Dictyostelium [39-42].
Truncation of the amino terminus of 34-kDa protein to
form CT results in a gain of function in activated actin
binding activity and formation of model Hirano bodies in
mammalian cells and in transgenic mice [41,43]. Model
Hirano bodies mitigate the transcriptional activation ac-
tivity of the APP intracellular domain (AICD), resulting
in a decrease in cell death [37]. Further, model Hirano
bodies decrease cell death potentiated by AICD and a
pseudohyperphosphorylated (PHP) tau mimic [44].
We investigated the association of both wild type and
mutant forms of tau with Hirano bodies, and their im-
pact on cell death pathways involving tau and AICD. We
report that nearly all tau isoforms and mutants tested
associate with model Hirano bodies in cells, and bind to
actin filaments in vitro. Cells expressing both tau and
AICD exhibited cell death that was greater than the sum
of that observed for tau and AICD alone. This synergistic
cell death involved activation of GSK3β, and was elimi-
nated by the presence of model Hirano bodies. These
results extend previous reports affirming a specific role
for Hirano bodies in aging and disease states and provides
further evidence that the presence of Hirano bodies may
have an important contribution to the pathogenesis of AD
and tauopathies such as FTDP-17.Results
The interaction of altered forms of tau with model Hirano
bodies and the impact of this interaction on disease path-
ways leading to cell death was investigated in this study.
Mutant tau proteins were chosen on the basis of previous
characterization of differential biochemical properties and
their effects on cell death. Expression of mutant tau found
in FTDP-17 (R5H, G272V, P301L, R406W) has differential
effects on cell death when expressed in cell cultures and in
various animal models of tauopathy [24,45,46] and these
effects may be attributable to the biochemical properties
of tau [47,48]. The tau mutant ΔK280 is representative of
a group of FTDP-17 mutants previously shown to have in-
creased susceptibility to aggregation compared to WT tau
[47-49]. However, whether or not tau polymerization is
directly neurotoxic continues to be a major question (for
review, see [1]). Previous studies have established a cell
culture, C. elegans, and mouse model of tau aggregation
through expression of a tau fragment comprising only the
microtubule binding domain with deletion of lysine 280
(K18ΔK280), which has a high propensity for β-structure
and aggregation [50-53]. Studies show that expression of
K18ΔK280 tau is more lethal than the same fragment
without the deletion of lysine 280 (K18), and causes cell
death prior to the formation of mature aggregations
[50,54,55]. The nomenclature of the tau variants and
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in Figure 1.
FTDP-17 tau mutants and Hirano bodies differentially
modulate cell death
The effect of FTDP-17 tau mutants (R5H, G272V, P301L,
R406W), 352PHP, and truncated K18 and K18ΔK280 tau
on cell death in the presence of model Hirano bodies was
investigated. As expected, exogenous expression of wild
type tau, 352PHP, and FTDP-17 tau mutants alone, R5H,
R406W, G272V, or P301L did not produce significant cell
death (Figure 2). Consistent with previous reports,
expression of K18ΔK280 resulted in significant cell
death compared to expression of K18 (Figure 2D, gray
bars ***p < 0.001). Coexpression of either 352WT,
441WT, 352PHP, R5H, R406W, K18, or K18ΔK280 tau
in the presence of model Hirano bodies resulted only in
background levels of cell death (Figure 2AB, check
bars). In contrast, expression of either G272V (**p <
0.01) or P301L (***p < 0.001) in the presence of model
Hirano bodies resulted in significant potentiation of cell
death (Figure 2C, check bars).
Actin binding
Tau has been previously shown to bind F-actin – albeit
not to saturation – and form F-actin bundles in solution
[26-28]. We determined the relative F-actin binding for
wild type tau and mutant forms of tau to investigate
whether the strength of actin binding may correlate with
cell death induced by tau and Hirano bodies. Using re-
combinant protein purified from E.coli and cosedimen-
tation with mixtures of F-actin, wild type and mutant
forms of tau do not achieve saturation binding to
F-actin as shown in Figure 3. R406W, G272V, P301L,
and 441WT bind F-actin better than 352PHP and R5H,
which are greater than 352WT (Figure 3). This result is
consistent with previous results of wild type recombinant
tau [27].
We investigated whether tau has an effect on formation
of model Hirano bodies since a prior report found that tau
promotes the formation of Hirano bodies [56]. Transient
expression of CT-GFP to induce model Hirano bodies andFigure 1 Schematic illustration of tau isoforms, phosphorylation sites
created in the 2N4R (441) tau isoform. Arrows represent boundaries of K18
and 2. R1, R2, R3, and R4 represent microtubule binding domain repeats 1–
mutations that occur in 352PHP tau [101]. This mutant was created in the 3either 352WT, 441WT, 352PHP, or P301L for 48 h did
not cause a change in the size of model Hirano bodies
(Additional file 1). Thus, Hirano bodies can form in the
absence of tau, and the presence of various forms of tau
does not modulate the formation of Hirano bodies.
Hirano bodies, tau, and AICD
Since previous reports have indicated that model Hirano
bodies protected against AICD-induced cell death in the
presence of 352WT or 352PHP [44], we investigated
whether model Hirano bodies would have an effect on cell
death induced by FTDP-17 tau (R5H, G272V, P301L,
R406W), or truncated tau (K18 or K18ΔK280) in the pres-
ence of AICD. Expression of AICD resulted in modest
levels of cell death (Figure 2A, white bars), and the
presence of model Hirano bodies significantly lowered
this death (white bars, *p < 0.05). Coexpression of either
352WT/AICD or 441WT/AICD (black bars) caused an in-
cremental increase in cell death that is similar to what is
expected from the additive effects of AICD alone and wild
type tau alone (see Table 1). In contrast, a marked po-
tentiation in cell death was observed upon coexpression
of 352PHP/AICD (black bars, Table 1) consistent with
previous data [44]. The potentiation of cell death is a
synergistic interaction between AICD and 352PHP since
the predicted amount of cell death due to AICD alone
plus that obtained with 352PHP alone is significantly less
than observed when the two are present together (Table 1).
The presence of model Hirano bodies protected against
cell death induced by either 352WT/AICD (stripe
bar, ***p < 0.001) or 441WT/AICD (stripe bar, **p < 0.01),
or 352PHP/AICD (stripe bar, ** p < 0.01).
The effect of FTDP-17 tau mutants on AICD-induced
cell death in the presence or absence of model Hirano
bodies was investigated. Similar to 352PHP tau, FTDP-
17 tau mutants (R5H, G272V, P301L, R406W) enhance
cell death in synergy with AICD (Figure 2B,C, black bars).
The amount of cell death observed is greater than ob-
tained from AICD alone plus that of tau alone (Table 1).
The presence of model Hirano bodies protected from
cell death due to either AICD/R5H or AICD/R406W
(Figure 2B, stripe bars **p < 0.01). However, in cellsand mutations. Point mutations R5H, G272V, P301L, and R406W were
(amino acids 244–372) [54]. N1 and N2 represent N-terminal exons 1
4. Yellow circles designate 10 serine/threonine to glutamic acid
52 tau isoform lacking N1, N2, and R2.
Figure 2 FTDP-17 tau and model Hirano bodies differentially modulate cell death. H4 cells were transiently transfected with equal amounts
of plasmid DNA encoding AICD and/or a single tau variant in the presence or absence of model Hirano bodies (CT-GFP). Model Hirano bodies
and a tau variant in the absence of AICD (check bars) or presence of AICD (striped bars). GFP and a tau variant in the absence of AICD (gray bars)
or the presence of AICD (black bars). A. Tau variants 352WT, 441WT, or 352PHP. B. Tau variants R5H or R406W. C. Tau variants G272V and P301L.
D. Tau variants K18 and K18ΔK280. Model Hirano bodies protect from cell death induced by AICD and tau, except for tau mutants G272V and
P301L. Note that G272V and P301L potentiate cell death in the presence of model Hirano bodies alone. *p < 0.05, **p < 0.01, ***p < 0.001. Error
bars represent the standard deviation.
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Hirano bodies had no effect on cell death (Figure 2C,
stripe bars). Expression of K18 and K18ΔK280 with
AICD increased cell death synergistically and additively,
respectively (black bars, *p < 0.05; Table 1). The presenceof model Hirano bodies lowered cell death (stripe bars
*p < 0.05) for both K18 and K18ΔK280. These data sug-
gest that model Hirano bodies have a differential effect
on cell death induced by tau and/or AICD, depending
on the tau variant used.
R406W G272 P301L 441WT
352WT
R5H 352PHP
Figure 3 Relative binding of recombinant tau to F-actin. Tau binds differentially to F-actin with binding of R406W (blue square), G272V (red
circle), P301L (blue triangle), and 441WT (green triangle) > 352PHP (purple diamond) and R5H (black circle) > 352WT (orange square). The curves
are to aid the reader and do not indicate biochemical binding curves. The standard deviations were not shown for clarity.
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of co-expression of AICD and tau variants suggests a con-
nection by one or more molecular pathways. The effect of
Hirano bodies on cell death may affect AICD, or tau, and/
or the synergy that arises from their interaction. Possible
routes of this interaction could involve activation of the
protein kinase GSK3β, phosphorylation of tau, binding of
tau to F-actin, or differential aggregation kinetics of the
tau variants.
Hirano bodies differentially influence cell death induced
by GSK3β and tau
GSK3β has been implicated in the pathogenesis of AD
(for review, see [57]). Specifically, GSK3β is thought to
become upregulated and/or activated by Aβ, AICD, and
the c-terminal 31 amino acids of APP (c31), triggering aTable 1 Additive versus synergistic cell death induced by co-e
Tau % Cell death (Additive) = GFP/AICD + GFP/tau
352tauWT 22.3% ± 1.46
441tauWT 20.9% ± 2.78
352tauPHP 21.7% ± 1.98
R5H 21.3% ± 2.49
K18 22.0% ± 4.24
K18ΔK280 42.5% ± 4.28
P301L 21.4% ± 2.97
G272V 21.9% ± 2.73
R406W 20.4% ± 3.93
Values of cell death obtained when GFP/AICD or GFP/tau transiently expressed wer
when GFP/AICD/tau were co-expressed. Synergistic cell death (bold entries) was ob
R406W. N.S. = not significant.cascade of signaling events leading to tau hyperphosphor-
ylation, apoptosis, and cell death [7,9,58]. The contribu-
tion of GSK3β and tau to cell death in the presence of
model Hirano bodies was investigated using a constitu-
tively active and a dominant negative form of GSK3β. Ex-
ogenous expression of a constitutively active mutant of
GSK3β (S9A) alone causes cell death similar to that of
AICD, and the presence of model Hirano bodies has no
effect on this death (Figure 4A, white bars). In contrast,
exogenous expression of GSK3β (S9A) in the presence
of 352WT or 352PHP causes significant potentiation of
cell death compared to GSK3β (S9A) alone (Figure 4A,
black bars ***p < 0.001 or **p < 0.01, respectively, Table 2).
Interestingly, although 352WT and 352PHP produce
similar amounts of cell death under these conditions,
441WT expression causes only an incremental increasexpression of AICD and tau
% Cell death ± SD (Actual) = GFP/AICD/tau p value
24.6% ± 1.74 N.S.
22.0% ± 2.36 N.S.
38.1% ± 4.35 p < 0.05
42.9% ± 4.09 p < 0.01
39.0% ± 6.98 p < 0.05
42.3% ± 4.61 N.S.
30.2% ± 3.79 p < 0.05
40.2% ± 1.40 p < 0.01
31.7% ± 2.70 p < 0.05
e added together and compared to the actual values of cell death obtained
served when AICD was co-expressed with 352PHP, R5H, K18, P301L, G272V, or
Figure 4 Model Hirano bodies differentially influence cell death in the presence of GSK3β (S9A) and tau. H4 cells were transiently
transfected with equal amounts of plasmid DNA. Control cells (white bars) were transfected with plasmid encoding either GFP or model Hirano
bodies (CT-GFP) in the presence or absence of constitutively active GSK3β (S9A). Cells were transfected with plasmid encoding GSK3β (S9A), a
single tau variant, and either GFP (black bars) or model Hirano bodies (check bars). A. Tau variants 352WT, 441WT, or 352PHP. B. Tau variants R5H,
G272V, P301l, or R406W. C. Tau variants K18 or K18ΔK280. D. Tau variants 441WT or P301L transfected with a lower amount of plasmid encoding
GSK3β (S9A). Model Hirano bodies significantly promote cell death induced by GSK3β (S9A) and tau except in tau mutants R5H, R406W, K18, and
K18ΔK280, where they have no effect. *p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent the standard deviation.
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is not significantly different from that expected from
cell death due to 441WT alone + GSK3β (S9A) alone
(Figure 4A, black bar; Table 2). Exogenous expression ofGSK3β (S9A) with either WT tau isoform or 352PHP in
the presence of model Hirano bodies causes even
further potentiation of cell death (Figure 4A, check
bars, ***p < 0.001 or **p < 0.01).
Table 2 Additive versus synergistic cell death induced by co-expression of tau and GSK3β (S9A)
Tau % Cell death (Additive) = GFP/GSK3β(S9A) + GFP/tau % Cell death (Actual) = GFP/GSK3β(S9A)/ tau p value
352tauWT 24.1% ± 1.44 57.3% ± 1.74 p < 0.005
441tauWT 24.7% ± 0.95 29.1% ± 2.77 N.S.
352tauPHP 25.5% ± 1.52 49.8% ± 3.63 p < 0.005
R5H 25.1% ± 1.62 43.4% ± 1.37 p < 0.005
K18 25.9% ± 1.40 46.3% ± 2.44 p < 0.005
K18ΔK280 46.4% ± 1.00 76.4% ± 4.84 p < 0.005
P301L 25.2% ± 1.37 55.3% ± 1.45 p < 0.005
G272V 25.8% ± 2.88 27.8% ± 3.13 N.S.
R406W 24.3% ± 1.14 43.0% ± 3.33 p < 0.005
Values of cell death obtained when GFP/GSK3β (S9A) or GFP/tau transiently expressed were added together and compared to the actual values of cell death
obtained when GFP/GSK3β (S9A)/tau were co-expressed. Synergistic cell death (bold entries) was observed when GSK3β (S9A) was co-expressed with 352PHP,
R5H, K18, K18ΔK280, P301L, or R406W. Interestingly, cell death in the presence of G272V was not affected by the presence of GSK3β (S9A). N.S. = not significant.
Table 3 The effect of tau phosphorylation on cell death
in the presence of model Hirano bodies
Sample %Cell death
Hirano body/GSK3β(K85A) 4.20 ± 0.77
Hirano body/G272V 17.90 ± 2.59
Hirano body/G272V/GSK3β(K85A) 10.20 ± 1.35
GFP/G272V 4.75 ± 0.74
GFP/G272V/ GSK3β(K85A) 5.80 ± 0.56
GFP/G272V + GFP/ GSK3β(K85A) 8.95 ± 2.06
Expression of GSK3β(K85A) reduced the synergistic cell death observed when
both G272V and model Hirano bodies are present, to an additive effect,
implying that the phosphorylation state is important.
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death induced by GSK3β (S9A) and model Hirano bodies
was investigated. Exogenous expression of tau mutants
R5H, P301L, and R406W in the presence of GSK3β (S9A)
increased cell death synergistically compared to the sum
of that observed with expression of GSK3β (S9A) and tau
alone (Figure 4B, black bars; Table 2). However, expression
of G272V tau in the presence of GSK3β (S9A) resulted in
only additive increases in cell death compared to ex-
pression of GSK3β (S9A) alone (Figure 4AB, Table 2).
We also observed differences in the ability of model
Hirano bodies to modulate cell death in the presence of
FTDP-17 mutant tau and GSK3β (S9A). Model Hirano
bodies enhanced cell death in the presence of GSK3β
(S9A)/G272V tau and GSK3β (S9A)/P301L tau (Figure 4B,
check bars ***p < 0.001), a result that occurred when either
G272V or P301L was expressed with model Hirano bod-
ies. However, model Hirano bodies had no effect on cell
death induced by GSK3β (S9A)/R5H tau or GSK3β (S9A)/
R406W tau (Figure 4B, check bars).
GSK3β (S9A) also significantly enhanced cell death in
the presence of K18 or K18ΔK280 compared to the
sum of the expression of GSK3β (S9A) and tau alone
(Figure 4C, black bars ***p < 0.001; Table 2). Model Hirano
bodies did not have a statistically significant effect on this
cell death (Figure 4C, check bars). We also measured cell
death under conditions in which expression of GSK3β
(S9A) did not induce significantly greater levels of cell
death than GFP controls (Figure 4D), showing that GSK3β
(S9A)-induced cell death is dose dependent. Similar to
previous results (Figure 4A-C), exogenous expression of
GSK3β (S9A)/441WT or GSK3β (S9A)/P301L potentiated
cell death compared to GSK3β (S9A) alone (Figure 4D,
black bars). In addition, the presence of model Hirano
bodies further increased this cell death compared to ex-
pression of GSK3β (S9A)/441WT (check bars, *p < 0.05)
or GSK3β (S9A)/P301L (check bars ***p < 0.001). These
results show that model Hirano bodies are not protectiveagainst cell death induced by GSK3β and tau, and depend-
ing on the mutation, may further increase cell death.
The contribution of dominant negative GSK3β (K85A)
[7,59] was used to test the role of GSK3β in cell death in-
duced by tau and model Hirano bodies. GSK3β (K85A)
was transiently co-expressed with model Hirano bodies in
the presence and absence of G272V (Table 3). The unex-
pectedly higher level of cell death due the presence of
G272V and model Hirano bodies was reduced in the pres-
ence of GSK3β (K85A) to that expected from the control
GFP/G272V +GFP/GSK3β(K85A) (Table 3, p < 0.02). This
result shows an interaction between F-actin and tau that is
more complex than F-actin binding alone and that phos-
phorylation of tau likely plays a role in cell death.
To determine whether cell death induced by combina-
tions of AICD and tau involve activation of GSK3β and
the phosphorylation state of tau, the effect of a dominant
negative GSK3β (K85A) was investigated (Figure 5). Ex-
pression of GSK3β (K85A) with GFP does not significantly
increase the cell death due to GFP alone (Figure 4, white
bars). Further, expression of AICD induces death of ap-
proximately 17% of cells, and this number is not signifi-
cantly changed in the presence of GSK3β (K85A)
(Figure 5A, white bars). Thus, cell death due to AICD
alone does not require activation by GSK3β. Cell death
Figure 5 GSK3β (K85A) differentially influences cell death in the presence of AICD and tau. H4 cells were transiently transfected with
equal amounts of plasmid DNA encoding GFP and different single tau variants in the absence of AICD (grey bars) or presence of AICD (black
bars) or dominant negative GSK3β (K85A) and tau in the absence of AICD (check bar) or presence of AICD (striped bar). A. Tau variant 352WT,
441WT, or 352PHP. B. Tau variant G272V or P301L. C. Tau variant R5H or R406W. D. Tau variant K18 or K18ΔK280. GSK3β (K85A) significantly
decreases cell death due to AICD and tau except in tau variants 352WT, 441WT, K18ΔK280 where there is no effect. *p < 0.05, **p < 0.01,
***p < 0.001. Error bars represent the standard deviation.
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and K18ΔK280 was unaffected by expression of GSK3β
(K85A) (Figure 5A and D, grey and checked bars). Cell
death due to tau + AICD was suppressed by expression
of GSK3β (K85A) for 352PHP, G272V, P301L, R5H, and
R406W, and K18 (Figure 5A-D, black and striped bars).
However, expression of GSK3β (K85A) had no effect on
cell death induced by AICD/352WT, AICD/441WT, or
AICD/K18ΔK280 (Figure 5A and D, black and striped
bars). Interestingly, cell death of all tau forms + AICD
that were suppressed by expression of GSK3β (K85A)
showed synergistic cell death in the presence of GSK3β
(S9A) (Table 2). These results imply that synergistic cell
death due to AICD and tau involve activation of GSK3β,
and that phosphorylation of tau is an important factor
to cell death. Cell death due to tau forms + AICD that
were not suppressed by expression of GSK3β (K85A)
had levels of cell death that was not significantly differ-
ent from the sum of that observed with tau and AICD
separately.Figure 6 Western blot analysis of GSK3β levels and tau
phosphorylation. HEK293 cells were transiently transfected with
equal amounts of plasmid. A. Expression of exogenous AICD
increases total GSK3β protein. Expression of CT-GFP in addition to
AICD reduces GSK3β to control levels. Expression of tau has no effect
on levels of GSK3β. NT = Not Transfected control. B. The presence of
exogenous CT-GFP increases phosphorylation of G272V and P301L
at Ser199/Ser202 and Thr231. Expression of CT-GFP has no effect on
441WT, R406W, or R5H tau phosphorylation at any epitope probed.Phosphorylation of tau
Results of cell viability in the presence of GSK3β (K85A)
suggest that 352PHP, R5H, R406W, G272V, and P301L
become phosphorylated by GSK3β in the presence of
AICD or CT-GFP. Previously, others have reported that
AICD is capable of increasing cellular levels of GSK3β
[7-9]. Therefore, western blot analysis was performed to
determine whether the presence of AICD and/or CT-
GFP impact the amount of GSK3β protein in our cell
culture system. The presence of exogenous AICD in-
creases total GSK3β levels above that of untransfected
cells and also of cells expressing tau only (Figure 6A).
Furthermore, expression of CT-GFP in the presence of
AICD and tau reduces the amount of GSK3β to that of
the control (Figure 6A). The increase of tau-induced
cell death due to the presence of G272V or P301L and
CT-GFP was reduced in the presence of GSK3β K85A
(Figure 5), suggesting CT-GFP may promote phosphor-
ylation of these tau mutants. To test this hypothesis,
western blot analysis was performed on different tau
mutants to determine if the presence of CT-GFP increases
phosphorylation at specific amino acids. 441WT, R406W,
and R5H tau showed no increase in phosphorylation at
Ser199, Ser202, or Thr231 in the presence of CT-GFP
(Figure 6B). Interestingly, both P301L and G272V have
increased phosphorylation at Ser199 and Ser202 and
Thr231 in the presence of CT-GFP (Figure 6B). P301L
and G272V exhibited synergistic cell death in the pres-
ence of CT-GFP (Figure 2C). These results show that
the ability of specific mutant tau proteins to induce cell
death in the presence of AICD or CT-GFP is due to
GSK3β phosphorylation of tau.Localization of tau and model Hirano bodies
Since preferential accumulation of different forms of tau
might indicate physiological function of Hirano bodies,
mutant tau and model Hirano body localization was inves-
tigated. H4 cells were transiently transfected with CT-GFP
to induce model Hirano bodies in the absence or presence
of one of the following FLAG-tagged tau constructs:
441WT, 352WT, R5H, G272V, P301L, R406W, 352PHP,
K18ΔK280 and K18. All FTDP-17 mutant tau proteins as
well as WT tau isoforms were present throughout the
model Hirano body or formed a ring-like structure around
the periphery of the model Hirano body shown in Figure 7.
The exception was 352PHP, which was diffusely localized
throughout the cell. Further, truncated tau mutants (K18
or K18ΔK280) also showed a strong nuclear localization.
These results show that regardless of mutations, tau shows
enrichment at sites of F-actin accumulation. However,
Figure 7 Immunofluorescence localization of tau and model Hirano bodies. H4 cells were transiently transfected with FLAG-tagged tau
constructs and CT-GFP to induce model Hirano bodies. 24 h post-transfection, cells were fixed and stained for good preservation of F-actin. Tau
was stained with anti-FLAG primary antibody and Alexa Fluor350 secondary antibody (blue). F-actin was stained using TRITC-phalloidin (red). All
tau isoforms colocalize with model Hirano bodies except 352PHP, which is localized diffusely throughout the cell. Tau variants examined were
control tau 352WT, 441WT, or tau mutants K18, R5H, G272V, P301L, R406W, K18ΔK280, and 352PHP. Scale bar = 20 μm.
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shown for 352PHP tau.
Localization of tau in human brain tissue was performed
to confirm that tau is present in Hirano bodies. In AD and
control brain sections, 4.1 and 2.7% of Hirano bodies are
well stained for tau, respectively (Figure 8). Localization of
phosphorylated tau (pTau199/202) to Hirano bodies was
observed only in AD brain sections and comprised 2.9% of
the total Hirano bodies. These findings are in agreement
with prior studies that report tau localized in a fraction of
all Hirano bodies in human hippocampus [32,33].Discussion
Tau contributes significantly to neurodegeneration in
FTDP-17, Alzheimer’s disease and other tauopathies by
aggregating to form oligomers, paired helical filaments
(PHF), and eventually large aggregates including neurofib-
rillary tangles (NFTs). In vitro, formation of oligomers and
higher order polymers of tau is thought to occur through
the process of nucleation, elongation, and/or autocatalytic
growth [60,61]. Regulatory pathways may influence the
availability of free tau, its phosphorylation state, propensity
to aggregate, and inducers of aggregation. Dissecting the
formation of oligomeric and higher order polymers of tau
in vivo and their contribution to cell death require probing
these pathways. In this study we have investigated the role
of Hirano bodies in modulating tau localization and cell
death due to tau.Figure 8 Immunohistochemistry localization of tau and Hirano bodie
embedded human brain sections using Tau5 or pTau-199/202 antibodies fo
antibodies colocalized with Hirano bodies in both Alzheimer diseased and
in Alzheimer diseased brains. Scale bar = 50 μmProposed cell death pathway involving Hirano bodies,
tau, AICD, and GSK3β
The role of tau in cell death induced by the presence or
absence of model Hirano bodies and/or AICD is a com-
plex intersection of several variables: 1) affinity of tau
for actin; 2) the phosphorylation state and location of
the phosphorylated amino acids on tau; and 3) the kin-
etics and propensity of tau to self-aggregate that could
depend on phosphorylation or other modification. As
shown in Figure 9, AICD causes significant cell death
when expressed alone. Similarly, expression of K18ΔK280
causes significant cell death unlike expression of all
other forms of tau tested (Figure 9). When coexpressed
with AICD, all tau mutants expressed except for 441WT,
352WT, and K18ΔK280 produced synergistic cell death
(Figure 9C). This cell death was ameliorated in the pres-
ence of model Hirano bodies, except in the case of P301L
or G272V tau (red lines). This could be due to reduction
of AICD or tau through indirect or direct binding to
F-actin in the model Hirano bodies and/or reduction of
GSK3β (Figure 6A) and thus affecting the phosphorylation
state of tau (Figure 6B). Interestingly, the expression of
model Hirano bodies and P301L or G272V tau led to sig-
nificant cell death in the absence of AICD (Figure 2C).
This process could be facilitated by a combination of bind-
ing to F-actin, increased phosphorylation that reduces
F-actin binding, and subsequent tau aggregation. The af-
finity of tau for F-actin itself is insufficient as R406W and
441WT bound F-actin as well as G272V and P301L.s in human brains. Immunohistochemistry was performed on paraffin
llowing an eosin counterstain to visualize Hirano bodies (arrows). Tau5
control brains while pTau-199/202 colocalized with Hirano bodies only
Figure 9 Model of the interplay between AICD, tau, and model Hirano bodies. A. The black line represents cell death initiated by “AICD
only” pathway involving Fe65, Tip60, p53, and caspases (41, 6). B. Blue line represent the modest levels of cell death initiated by “tau only”
including K18ΔK280 alone and low levels of cell death from all other tau alone (green boxes). C. The pink arrows represent the synergistic cell
death due to AICD and either G272V, P301L, K18, RH5, R406W, or 352PHP tau. 441WT, 352WT, and K18ΔK280 do not synergize with AICD to
promote cell death. D. Model Hirano bodies protect against AICD -induced cell death and cell death initiated by AICD and K18, RH5, R406W, or
352PHP tau (red lines). In contrast, model Hirano bodies potentiate AICD- induced cell death in the presence of either P301L or G272V tau (green
lines). Model Hirano bodies alone have no impact on K18, R5H, R406W, 352PHP, 441WT, 352WT, or K18ΔK280 tau -induced cell death or have
negative consequences. In addition, the synergistic cell death induced by AICD in the presence of G272V or P301L tau is not affected by the
presence of model Hirano bodies. E. Expression of the dominant negative GSK3-β (K85A) prevents cell death initiated by synergistic interaction of
AICD and tau or model Hirano bodies and G272V or P301L tau (red lines).
Spears et al. BMC Neuroscience 2014, 15:74 Page 12 of 20
http://www.biomedcentral.com/1471-2202/15/74We also find that expression of a dominant negative
form of GSK3β mitigates cell death due to the synergistic
effect of AICD and tau in most cases (Figure 5, Figure 9E).
This result underscores the importance ofGSK3β activation
and tau phosphorylation in the synergistic interaction of
AICD and tau. In support of this, expression of dominant
negativeGSK3β (K85A)doesnot reducecell deathdue toex-
pression of AICD alone, or AICD and K18ΔK280, as most
GSK3β phosphorylation sites are absent from this mu-
tant. We show that expression of GSK3β (K85A) ame-
liorates cell death due to G272V in the presence of
Hirano bodies, further substantiating the role of GSK3β
phosphorylation in our system, even in the absence of
exogenously expressed AICD. In summary, these results
support the assertion that a combination of tau phos-
phorylation and aggregation leads to cell death, which
may be either enhanced or mitigated by the presence of
model Hirano bodies depending on the form of tau and
state of its modification.
These new results resolve an apparent contradiction in
previous literature. Expression of mutant forms of tau
were shown to induce cell death only after overexpres-
sion of actin and subsequent formation of actin-richstructures in a Drosophila model [24]. However, model
Hirano bodies were previously reported to reduce toxicity
associated with tau under certain conditions [44]. Here we
show that Hirano bodies can both promote and protect
against cell death initiated by tau depending on the type of
tau expressed.
Tau and actin
Multiple studies point to the role of tau as an actin bind-
ing protein [25-28,62-66]. However, this idea is not with-
out controversy. Studies of tau-actin interactions utilize
a range of experimental approaches that yield differential
results [67]. Tau has been shown to bind and bundle
actin in vitro [24,27,28,62]. Tau bound weakly to actin
and did not reach saturation [27]. In competitive binding
studies with actin, the preferred substrate of tau is
tubulin polymerized into microtubules [27,65]. Our
study is the first to show that all tau mutants tested are
able to bind to F-actin with the resultant binding R406W,
G272V, P301L, and 441WT > 352PHP and R5H > 352WT
(Figure 3). R406W, G272V, and P301L have the highest
affinity for F-actin yet only G272V and P301L potentiate
cell death in the presence of model Hirano bodies and/or
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binding affinity of the various tau mutants does not
explain the differential effect of tau on cell death in the
presence of model Hirano bodies. However, since re-
combinant protein produced in E.coli was used, the im-
pact of tau post-translational modifications on F-actin
binding was not measured. Other results reported in
this study imply that the phosphorylation state of tau is
important. In the presence of constitutively active GSK3β
(S9A), model Hirano bodies potentiate cell death in the
presence of tau (see Table 2). In addition, only a small per-
centage of Hirano bodies in AD brain contain phosphory-
lated tau (Figure 8). Another group was unable to detect
pTau-202/205 in Hirano bodies from Alzheimer’s patients
[68]. It is possible that colocalization of tau with Hirano
bodies varies from patient to patient and is heavily influ-
enced by post-translational modification, and aggregation
state given that Hirano bodies frequently occur in NFT-
containing neurons [38]. Consistent with this hypothesis,
others have shown that phosphorylation of tau at certain
sites reduces, but may not abolish its ability to associate
with actin filaments [69]. Conversely, studies have sug-
gested that minor phosphorylation of certain residues may
enhance actin binding [24,27,70]. This suggests a complex,
dynamic relationship between tau and actin. This may ex-
plain why 352PHP binds F-actin in vitro (Figure 3), but
does not co-localize with model Hirano bodies (Figure 7).
In vivo, tau association with actin has been shown to be
critical for tau-induced neurodegeneration [24]. We can-
not rule out that other modes of actin and tau interaction
may be occurring such as intermediate binding proteins
or other protein modifications. For example, tau also binds
to Fe65 [71], and Fe65 is known to be enriched in Hirano
bodies [37].
Phosphorylation of tau
Studies characterizing FTDP-17 tau mutants demon-
strated that tau was highly phosphorylated, and de-
pending on the mutation, differentially phosphorylated
[72-74]. This differential phosphorylation also affects
the ability of tau and its mutants to bind to microtu-
bules [75], affects microtubule dynamic instability, and
promotes microtubule assembly (for a review, see [76]).
It is also well known that tau phosphorylation at mul-
tiple sites in vivo decreases its association with micro-
tubules [67,77], thus making tau available to aggregate.
Hyperphosphorylated tau has a tighter, more folded
conformation and in some cases, an increased propen-
sity to aggregate [14,74,78-83].
In all tau constructs tested except for R5H, R406W,
K18, or K18ΔK280, expression of exogenous constitu-
tively active GSK3β (S9A) and tau in the presence of
model Hirano bodies strongly potentiated cell death com-
pared to expression of GSK3β (S9A) and tau (Figure 4).Since GSK3β phosphorylates many substrates, results
need to be interpreted with some caution. However, our
results suggest that GSK3β or another kinase induces
formation of hyperphosphorylated tau species. Model
Hirano bodies could potentiate cell death by increasing
the local concentration of tau through F-actin binding,
serving as the nucleation agent in subsequent tau phos-
phorylation and aggregation. G272V and P301L have a
higher propensity to aggregate than 441WT (see below
[47]), and may therefore aggregate and induce cell death
more easily in the presence of Hirano bodies. G272V
and P301L were more phosphorylated in the presence
of model Hirano bodies (Figure 6), lending credence to
this supposition. Further experiments show that expres-
sion of dominant negative GSK3β (K85A) in the pres-
ence AICD and tau decreases levels of cell death to that
expected from an additive effect of cell death induced
by AICD + tau alone (Figure 2, Table 1). However,
model Hirano bodies did not further enhance cell death
in the presence of R406W shown previously to be hypo-
phosphorylated in the presence of GSK3β [7,58] or tau
mutants that did not contain the majority of GSK3β
phosphorylation sites (K18 and K18ΔK280). Expression
of dominant negative GSK3β (K85A) in the presence of
G272V and model Hirano bodies lowered cell death to
that expected of an additive effect of cell death induced
by G272V +model Hirano bodies alone (Figure 5). This
may suggest a complementary role for phosphorylation
and aggregation.
Consistent with this, in vitro studies characterizing the
352PHP tau mutant show that these mutations collectively
inhibit aggregation compared to WT tau [84]. Therefore,
transient phosphorylation and dephosphorylation of tau
may be critical to formation of a pathologically relevant
tau species. This may explain why expression of 352PHP
tau and model Hirano bodies does not cause increased cell
death in our system. It has been shown that phosphoryl-
ation of specific residues on tau is required to prime tau
for additional phosphorylation [85-88], and that 352PHP
becomes phosphorylated in cell cultures under certain
conditions at other serine/threonine residues that are not
mutated [89]. Therefore, the amino acid charge substitu-
tions used to create the phosphorylation mimics on
352PHP may prime phosphorylation at other sites. This
could explain why expression of either AICD or GSK3β
with 352PHP results in a synergistic cell death phenotype.
These results support the hypothesis that model Hirano
bodies enhance cell death in the presence of highly phos-
phorylated tau, and reduce cell death in the presence of
other tau variants.
Aggregation of FTDP-17 mutant tau
The ability of tau to promote cell death in the presence
of model Hirano bodies and/or AICD correlates most
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Multiple studies show that FTDP-17 tau mutants vary
widely in their ability to form PHFs and NFTs in vitro,
in cell culture, and in vivo as well as the kinetics in
which they form [90]. Studies with recombinant tau ob-
tained from bacteria showed that ΔK280(441tau) had a
greater propensity to form paired helical filaments than
P301L > G272V > R406W > 441WT with a faster kinetic
speed [47]. Tau mutants P301L and K18ΔK280 show the
greatest tendency to aggregate [47], and potentiated the
highest levels of cell death in the presence of model
Hirano bodies. All tau mutants except for K18ΔK280
were incapable of inducing cell death alone consistent
with previous reports [50,54]. The ability of K18ΔK280
to cause cell death was attributed to the ability of this
fragment to aggregate since mutation of hexapeptide
motifs in tau essential for β-structure and aggregation re-
duced cell death and rescued neurodegeneration [55,91].
Model Hirano bodies have no effect on cell death initiated
by expression of exogenous K18ΔK280. Because this mu-
tant is capable of initiating cell death on its own, it likely
does not need model Hirano bodies to further aid its ag-
gregation. Although little is known about the R5H tau mu-
tation, R5L has been characterized in vitro with increased
nucleation rate of aggregation and increased numbers of
tau filaments [92], a trait shared with R5H [18]. R406W
tau does not robustly aggregate in vitro or in cell cultures
[92-95]. In fact, R406W tau has been shown to be hypo-
phosphorylated in resting cells compared to WT tau
[93,95], and hypophosphorylated when exposed to GSK3β
in vitro [94]. Thus, tau phosphorylation may be related to
tau aggregation and cell death. The specific tau species
responsible for potentiating cell death in our model is
unknown, and more studies are needed to determine
whether further tau modification and proteolytic process-
ing contributes to cell death. In support of a relationship
between aggregation and cell death, some FTDP-17
patients exhibit more aggressive symptoms than AD
patients, coincident with robust tau pathology at an
earlier age of onset (for review, see [96]).
A possible mechanism for the interaction of model
Hirano bodies and tau is that model Hirano bodies in-
crease the local concentration of tau through a direct or
indirect interaction. All the full-length tau proteins
bound F-actin in our study and all tau proteins with the
exception of 352PHP were enriched with model Hirano
bodies (Figures 3 and 7). While tau binds with a lower
affinity to actin than microtubules, the concentration of
F-actin in a Hirano body could be 360–600 μM based
on the actin concentration in F-actin solutions bundled
by the Dictyostelium 34 kDa actin bundling protein
[97]. The high local concentration of F-actin in a model
Hirano body could compensate for weak tau binding. Phos-
phorylation, aggregation, or other protein modificationscould become more favorable due to the high local con-
centration. Tau mutants most prone to aggregation then
initiate cell death. Previous studies with recombinant tau
induced to aggregate by the presence of heparin showed
that both P301L and G272V aggregated faster and to a
greater extent than R406W or 441WT [47]. The truncated
K18ΔK280 aggregated exceptionally quickly in contrast to
K18. Model Hirano bodies were not able to protect against
cell death in the presence of these aggregation-prone tau
mutants alone or in addition to AICD. In contrast, WT
tau isoforms and tau mutants R406W and R5H did not
cause cell death in the presence of model Hirano bodies,
and model Hirano bodies were able to protect from cell
death induced by these tau mutants in the presence of
AICD. These forms of tau were slower to aggregate and
did so to a smaller extent than P301L, G272V, or
K18ΔK280 [47].
AICD and tau
Our data is consistent with the idea that tau significantly
contributes to cell death in the presence of AICD. This
complements previous results showing that expression
of exogenous c31/APP/352PHP tau or AICD/352PHP
tau results in a potentiation of cell death compared to
cells expressing AICD or 352PHP alone [44]. In this
study, expression of all tau forms tested enhanced cell
death in the presence of AICD (albeit at different levels)
to a level that was significantly greater than the sum of
AICD and tau expressed separately with the exception of
352WT, 441WT, and K18ΔK280 (Table 1). It is note-
worthy that exogenous expression of dominant negative
GSK3β (K85A) with AICD and all forms of tau that pre-
viously induced synergistic cell death decreased to an
additive sum of AICD alone plus tau alone, while AICD
and all forms of tau that do not induce synergistic cell
death were unaffected by GSK3β (K85A). In addition, the
presence of model Hirano bodies with AICD and tau de-
creased the amount of GSK3β. These results support a
model in which AICD potentiates cell death in the pres-
ence of tau and that phosphorylation of tau is important
to that process. AICD has been shown to up-regulate or
be upstream of GSK3β activation [7]. Our results strongly
support the conclusion that the interplay between AICD
and tau involves activation of GSK3β and phosphorylation
of tau, and that there are at least two major effects of
AICD. AICD alone activates Fe65, Tip60, and caspases,
while the interaction of AICD with tau to cause cell death
requires activation of GSK3β.
Conclusion
We provide further evidence that Hirano bodies have a
specific effect on the pathogenesis of neurodegenerative
disease, with respect to tau and C-terminal fragments of
APP. We suggest that Hirano bodies do not serve a
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cytosolic proteins, but rather protect against cell death
initiated by AICD and mitigate or enhance cell death
dependent on the biochemical properties of tau. This
data complements key discoveries made in transgenic
animal models and neuronal cell culture reporting ab-
normal rearrangement of F-actin during cell stress or
neurodegeneration, and suggest that Hirano bodies play
a complex role in the pathogenesis of disease.
Methods
Plasmids
CT-EGFP was utilized to induce model Hirano bodies
as previously described [42,44]. Other plasmids utilized
encoded GFP (pEGFP-N1, Clontech, Mountain View,
CA), AICD (APPc58-myc, c-terminal 58 amino acids of
APP-695, a generous gift from Bradley Hyman, Harvard
Medical School) [98], and HA-tagged GSK3β (Addgene
plasmid 15994) [99]. GSK3β (S9A) (constitutively active)
[100], and GSK3β (K85A) (dominant negative) [7,59] were
constructed from HA-GSK3β using a QuikChange II
XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla
CA) using mutagenic primers K85A 5’GAACTGGTCGC
CATCAAGAAAGTATTGCAGGAC 3’ and S9A 5’ CCA
GAACCACCGCCTTTGCGGAGAGC 3’. The coding se-
quences of these plasmids were confirmed by sequencing.
A single MAPT gene in the central nervous system
generates six tau isoforms by alternative splicing of its
pre-mRNA. Isoforms ranging in size from 352–441 resi-
dues differ by exclusion or inclusion of exons 2,3, and
10. Plasmids were constructed to express wild type tau
(352WT or 441WT) or mutant forms (352PHP, R5H,
G272V, P301L, R406W, K18, or K18ΔK280) in either
mammalian or bacterial cells. 352PHP is a tau mutant
created in the shortest tau isoform (352WT) in which
10 serine/threonine residues (S198, S199, S202, T231,
S235, S396, S404, S409, S413, and S422) were mutated to
glutamic acid to mimic a hyperphosphorylated state (gen-
erous gifts from Roland Brandt, University of Osnabrück,
Osnabrück, Germany) [101] as shown in Figure 1. K18
comprises the microtubule-binding domain (amino acids
Q244 to E372, numbering from the 441 length tau) [47].
To generate N-terminal FLAG-tagged tau constructs
with a CMV promoter for expression in mammalian
cells (Figure 1), the coding sequence of 352PHP was
digested from the 352PHP plasmid with ClaI. Using the
coding sequence of 441 length human WT tau (441WT)
in pET-29b (Addgene plasmid 16316) [102] as a template,
ClaI restriction sites were introduced through PCR, and
441WT coding sequence was cloned into the ClaI site of
the remainder of the 352PHP plasmid backbone con-
taining the FLAG-tag and CMV promoter. Tau mutants
in the 441 length tau in either the mammalian or bacterial
expression plasmids were constructed using a QuikChangeII XL Site-Directed Mutagenesis Kit (Stratagene, La
Jolla CA). Primers for mutagenesis were: ΔK280 (deletion





TG. Tau constructs K18 and K18ΔK280 were gener-
ated by the introduction of ClaI sites to the 5’ and 3’
end of K18 or K18ΔK280 using either the 441WT or
ΔK280 441WT as template, digesting the PCR prod-
ucts, and ligating into the ClaI site of the remainder
of the 352PHP plasmid backbone after deletion of the
coding sequence. The coding sequences of all plas-
mids were verified by sequencing.
Immunofluorescence
Hirano bodies have been proposed to have a glial origin
[103], and because glial cells have been shown to be im-
portant mediators of cell death induced by Aβ and tau
[104], H4 human astroglioma cells were utilized. Fur-
thermore, H4 cells have been shown to contain nearly
undetectable levels of endogenous tau [105,106]. H4
astroglioma cells (American Type Culture Collection,
Manassas, VA) were cultured in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% fetal
bovine serum (Atlanta Biologicals, Flowery Branch, GA)
at 37°C and 5% CO2. H4 cells were plated onto glass
coverslips and allowed to adhere for 24 h. Cells were
transiently transfected with equal amounts of plasmid
(1 μg each) using Lipofectamine LTX (Invitrogen, Carlsbad,
CA) according to manufacturer’s instructions. Cells
were processed after 24 h for immunofluorescence as
previously described [42]. Coverslips were visualized with
a Zeiss Axioobserver Z1 equipped with an AxioCam
MRm controlled by AxioVision4.6 software. Antibodies
used were anti-FLAG rabbit antibody to label tau
(Sigma-Aldrich, St. Louis, MO), and Alexa Fluor 350
conjugated anti-rabbit secondary antibody (Molecular
Probes, Eugene, OR). F-actin was visualized using
TRITC-conjugated phalloidin (Sigma-Aldrich, St. Louis,
MO), and nuclei were stained with DAPI (Sigma-Aldrich,
St. Louis, MO). Characterization of the types of actin-rich
structures was performed on H4 cells transfected as de-
scribed above and processed for immunofluorescence
48 h after transfection. CT-GFP-rich structures were
characterized having normal cellular localization, fibrillar
structures, Hirano bodies or large Hirano bodies. Hirano
body size was determined using NIH ImageJ using the
threshold function to eliminate user bias. Large Hirano
bodies are those in the fourth quartile. Significance be-
tween samples was determined using the non-parametric
Mann–Whitney test. Experiments were performed in a
minimum of triplicate.
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All samples were de-identified and coded only by sample
number (see Table 4), and supplied as eight-micron,
paraformaldehyde-fixed paraffin sections mounted on
slides. Mounted sections were dewaxed in xylene and
rehydrated in an ethanol gradient prior to antigen retrieval
in boiling 10 mM sodium citrate plus 0.05% Tween 20
pH 6.0 for 20 minutes. Endogenous peroxidase activity
was inhibited by incubating sections in 3% hydrogen per-
oxide for 10 minutes prior to washing with phosphate
buffered saline (PBS) and blocking with 10 mg/ml bovine
serum albumin in PBS overnight. Samples were stained
for total tau using mouse tau 5 antibody (1/400 in PBS,
4% BSA) (Santa Cruz Biotechnology, Dallas, TX), or tau
phosphorylated at serine 199/202 using rabbit anti-
pTau199/202 (1/300 in PBS, 4% BSA) (Sigma-Aldrich
Chemical Co, St. Louis, MO). Anti-mouse and anti-rabbit
biotinylated secondary antibodies (1/800 in PBS) (Sigma-
Aldrich Chemical Co, St. Louis, MO) followed by a
streptavidin-HRP polymer complex (1/1000 in PBS) with
diaminobenzidine enhanced substrate system (Vector
Laboratory, Burlingame, CA) were utilized as a detection
system. Samples were counterstained with hematoxylin/
eosin (Sigma-Aldrich Chemical Co, St. Louis, MO) to
visualize Hirano bodies. All protocols were approved
by the University of Georgia Institutional Biosafety
Committee and the Institutional Review Board.
Cell death assays
24 hours prior to transfection, 8,000 H4 cells/well were
plated into 96-well plates (Nalge Nunc, Rochester, NY).
Cells were transiently transfected with equal amounts
of plasmid (250 ng each) using Lipofectamine LTX
(Invitrogen, Carlsbad, CA) according to manufacturer’s
instructions. In some experiments, the amount of GSK3β
(S9A) plasmid was reduced (150 ng) to examine its dose
dependent effect while the amounts of the other plas-
mids were kept constant. 24 hours post-transfection, cell
death assays were performed as previously described [44].
Briefly, cells were incubated with 9 nM Sytox Orange, aTable 4 Samples of human hippocampus were obtained
from the Alzheimer’s Disease Research Center at Emory
University
Case number Age at death Race/sex
AD-1 81 Male
AD-2 83 Caucasian male
AD-3 66 African American female
Control-1 88 Caucasian female
Control-2 94 Caucasian male
Samples were screened for presence of Hirano bodies, and were derived from
patients with AD, or control subjects that had no known history of
neurological disease and no neuropathological changes indicative of
neurodegenerative disease at autopsy.cell impermeable nucleic acid dye (Invitrogen, Carlsbad,
CA), and 264 μM Hoechst 33258 (Sigma-Aldrich
Chemical Co, St. Louis, MO) for 15 min at 37°C and 5%
CO2. Due to inefficient transfection, GFP was used as a
transfection control. Sytox Orange positive fluorescence
was used to indicate dead cells. A minimum of 80 cells
was counted per sample and each condition was sampled
at least three independent times. Analysis of statistical sig-
nificance was performed using Student’s t-test. The inter-
actions of multiple components and their contributions to
cell death were analyzed by using propagation of error,
comparing the calculated sum and standard deviations of
cell death observed when the two components were separ-
ate to that observed when they were present in the assay
together to determine the error of the calculated sum.
This strategy and applying Student’s t-test allowed de-
termination of whether the cell death observed when
the two components were present together was signifi-
cantly greater than expected, suggesting a biological and/
or molecular interaction.
Protein purification
Expression of wild type and mutated forms of tau in
pET29-b was induced by the addition of 1 mM IPTG in
E.coli Bl-21(DE-3) with the exception of 352PHP which
required no IPTG. Recombinant tau proteins were puri-
fied as previously described [107] with the following modi-
fications. Cells were lysed by the addition of 0.2 mg/ml of
lysozyme in the bacterial resuspension buffer and stirred
until lysis was complete. The lysate was sonicated prior to
the addition of NaCl and subsequent boiling. The lysate
was clarified by ultracentrifugation and the supernatant
was diluted with cation exchange buffer A without NaCl
to a final concentration of 50 mM NaCl, and applied to
CM-cellulose column (GE Healthcare Life Sciences,
Piscataway, NJ). The column was washed with cation
exchange buffer A until the OD reached baseline levels
and subsequently eluted with a linear gradient 0.05–0.4
M NaCl gradient. Fractions containing tau were
identified by SDS-PAGE, collected, diluted with cation
exchange buffer A without NaCl to a final concentration
of 50 mM NaCl and concentrated on CM-cellulose. The
mutant tau was eluted with cation exchange buffer with
0.6 M NaCl. Fractions containing the mutant tau were
identified by OD280 nm, sedimented at 13,000 × g for
15 min at 4°C, and the supernatant applied directly to
sephacryl S-200 (GE Healthcare Life Sciences, Piscataway,
NJ) column equilibrated with 10 mM HEPES, pH 7.4,
150 mM NaCl, 1 mM DTT, and 0.02% sodium azide.
Fractions containing tau were identified by SDS-PAGE.
Individual fractions containing the highest concentrations
of tau were frozen at -80°C and used without further con-
centrating. Five hours prior to use, the tau was dialyzed
versus cosedimentation buffer (see below).
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one powder [108,109] and further purified by application
to sephadex G-150. The actin was maintained for up to
1 week in cosedimentation buffer (10 mM PIPES, pH 7.0,
100 mM KCl, 1 mM MgCl2, 1 mM ATP, 1 mM DTT, and
0.02% sodium azide) with daily buffer changes. The pro-
tein concentrations of actin and tau were determined
using bicinchoninic acid method (Pierce Protein Biology,
Rockford, IL) [110] with bovine serum albumin as a
standard.
Cosedimentation assays were performed as previously
described [111]. F-actin and/or tau mixtures were incu-
bated 2 h prior to ultracentrifugation. The samples
were analyzed by SDS-PAGE and quantified utilizing
ChemiDoc™ MP System and Image Lab™ software (Bio-
Rad Laboratories, Hercules, CA). The amount of tau in
the pellets was corrected for the small amount of tau
alone found in the pellet. Experiments were performed
in a minimum of triplicate.
Western blot
HEK293T cells (American Type Culture Collection,
Manassas, VA) were cultured in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% fetal
bovine serum (Atlanta Biologicals, Flowery Branch,
GA) at 37°C and 5% CO2. They were plated at a density
of 4 × 105 cells per 60 mm diameter dish. Cells were
transfected with equal amounts of plasmid (2.5 μg each)
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA)
according to manufacturer’s instructions. At 48 hours
after transfection, cells were washed twice with ice-cold
PBS and lysed with 20 mM Tris, pH 7.5, 1% triton-X100,
0.1% SDS, 0.5% deoxycholic acid, and 10% glycerol with
10 μL protease inhibitor cocktail (5 mM EGTA, 1 mM
DTT, 100 mM leupeptin, 10 mM pepstatin, 0.1 M PMSF,
0.1 M benzamidine, and 0.5 M ε-aminocaproic acid). Cell
debris was separated from total homogenate by centrifuga-
tion at 13,000 g for 15 min at 4°C. The supernatant was
stored at −80°C until used. Protein concentrations of the
supernatants were determined by bicinchoninic acid assay
using BSA as a standard [110]. For western blot analysis,
samples were loaded at equal total protein, separated by
SDS-PAGE, and transferred to nitrocellulose membranes.
Blots were blocked in 5% nonfat dry milk in TBST
and probed using with either rabbit anti-pTau199/202
(1/4500) (Sigma-Aldrich Chemical Co, St. Louis, MO),
rabbit-anti pTau231 (1/2000) (Acris Antibodies, San
Diego, CA), goat-anti pTau396 (1/2000) (Santa Cruz
Biotechnology, Dallas, TX), rabbit anti-GFP (1/5000)
(Sigma-Aldrich Chemical Co., St. Louis, MO), mouse anti-
tau5 (1/5000) (Santa Cruz Biotechnology, Dallas, TX),
mouse anti-alpha tubulin (1/8000) (Millipore, Billerica,
MA), mouse anti-myc (1/8000) (Cell Signaling Technology,
Danvers, MA), or rabbit anti-GSK-3β (1/1000) (SantaCruz Biotechnology, Dallas, TX). After three washes
with TBST, blots were incubated with either goat
anti-mouse horseradish peroxidase, goat anti-rabbit horse-
radish peroxidase (1/10000) (Pierce-lab, Rockford, IL),
or donkey anti-goat horseradish peroxidase (1/8000)
(Millipore, Billerica, MA) and detected by chemilumines-
cence using SuperSignal Western Dura Extended Duration
Substrate (Thermo Scientific, Rockford IL). Images were
captured utilizing ChemiDoc™ MP system and Image Lab™
software (Bio-Rad Laboratories, Hercules, CA).
Blots were performed in duplicate.
Additional file
Additional file 1: Figure S1. Mutant tau does not affect model Hirano
body formation. H4 cells were transiently transfected with equal amounts
of plasmid DNA encoding CT-GFP to induce model Hirano bodies in the
absence (white bars) or presence of either 352WT (stripe bar), 441WT
(grey bar), 352 PHP (black bar), or P301L (crosshatch bar). Cells were fixed
after 48 hrs. Model Hirano bodies were characterized as normal, fibrillar,
Hirano body, or large Hirano body as determined by GFP fluorescence.
There is no difference between the populations of cells. Scale bar = 20 μm.
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